ProCE Banner Activity

Drs Daniel R. Kuritzkes and Darcy Wooten: Key HIV Studies From CROI 2024

Video

Hear from expert faculty as they present their insights on the most clinically relevant new data presented at CROI 2024, including discussions on long-acting ART, comorbidities and coinfections, and potential future treatment options for HIV.

Released: March 27, 2024

Expiration: March 26, 2025

Share

Faculty

Daniel R Kuritzkes

Daniel R Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Darcy Wooten

Darcy Wooten, MD, MS

Professor of Medicine
Division of Infectious Diseases
Washington University
St Louis, Missouri

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported through independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Disclosure

Primary Author

Daniel R Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel R. Kuritzkes, MD: consultant/advisor/speaker: AbbVie, Atea, Decoy, Gilead, GlaxoSmithKline, Janssen, Merck, Moderna, Pfizer, Shionogi, ViiV.

Darcy Wooten, MD, MS

Professor of Medicine
Division of Infectious Diseases
Washington University
St Louis, Missouri

Darcy Wooten, MD, MS, has no relevant financial relationships to disclose.